Table 3.
Ongoing CAR-T therapy clinical trials in the United States for the treatment of relapsed or refractory acute myeloid leukemia.
| National Clinical Trial (NCT) Number | Study Title | Intervention/Treatment | Phase |
|---|---|---|---|
| NCT04219163 | Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen | Biological: CLL-1.CAR T cells | Phase 1 |
| NCT03904069 | Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML | Drug: AMG 553 | Phase 1 |
| NCT02159495 | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | Biological: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes | Phase 1 |
| NCT03971799 | Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia | Biological: CD33CART | Phase 1 Phase 2 |
| NCT03766126 | Lentivirally Redirected CD123 Autologous T Cells in AML | Biological: CART123 cells | Phase 1 |
| NCT04678336 | CD123 Redirected T Cells for AML in Pediatric Subjects | Biological: CART123 cells | Phase 1 |
| NCT03927261 | PRGN-3006 Adoptive Cellular Therapy for Relapsed or Refractory AML or Higher Risk MDS | Drug: PRGN-3006 T Cells | Phase 1 |
| NCT03190278 | Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01) | Biological: UCART123v1.2 | Phase 1 |
| NCT04789408 | Study Evaluating the Safety of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia | Biological: KITE-222 | Phase 1 |
| NCT04167696 | Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1) | Biological: CYAD-02 | Phase 1 |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | Biological: WU-CART-007 | Phase 1 |
| NCT05672147 | CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia | Biological: Anti-CD33 CAR T-cells | Phase 1 |
| NCT05442580 | CART-38 in Adult AML and MM Patients | Drug: CART-38 cells | Phase 1 |
| NCT05457010 | Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS | Biological: SPRX002 Biological: ARC-T Cells |
Phase 1 |